But if you were the CEO of Lilly and you know that Nimo is just around the corner picking up steam, would you let it take a bite out of your $1.5 billion a year drug (erbitux)? Or let it join your team?
Lilly needs a pipeline in the worst way. I've also been thinking that Incyte could be a target considering their lucrative RA partnerships and the fact that so many pieces of Incyte's pipeline are not partnered. Heck, they could easily do a deal with YMI that thrills shareholders and still have enough room to do a whole lot more.
Did anyone see that the US might be easing travel restrictions to Cuba. That can only help in terms of the eventual approval of nimotuzumab.